drugset / Trial / NCT07417189
A Phase I/II Study of ABSK141 in Patients With Advanced Solid Tumors ( ABSK141-101 )
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a first-in-human (FIH), exploratory, multicenter, open-label, phase I/II study of ABSK141 in patients with advanced solid tumors to to evaluate safety, tolerability, PK and optimize the dosage.
Timeline
- Start
- 2026-03-02
- Primary completion
- 2028-12-30
- Completion
- 2029-07-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ABSK141 | Unknown | 400 mg | Oral |
| Subject | ABSK141 | Unknown | 800 mg | Oral |
| Subject | ABSK141 | Unknown | 1200 mg | Oral |
Indications
No indication recorded.